The blood group Rh(CE) polypeptide is a membrane protein encoded by the RHCE gene in humans. It is also known as Rh polypeptide 1 (RhPI), Rh30A, RhIXB, Rhesus C/E antigens. RHCE has also recently been designated as CD240CE (cluster of differential 240 CE). RHCE has four major alleles encoding a combination of Ce, Ce, Ce, and Ce antigens, 4. The RHD and RHCE genes, each consisting of 10 exons, represent a group of genes. The Rh blood group system is the second most important in the blood group, second only to the ABO blood group. It is also one of the most polymorphic types of blood, with mutations due to deletions, gene conversions, and erroneous mutations. The gene encoding the RhC and RhE antigens on a single polypeptide is a member of the Rh blood group. The group also includes the gene which encodes the RhD protein. According to the presence or absence of highly immunogenic RhD proteins on the erythrocyte surface, the classification of Rh-positive and Rh-negative individuals is determined. Selective splicing of this gene results in four different forms of transcript variants.
|Basic Information of RHCE|
|Protein Name||Blood group Rh(CE) polypeptide|
|Aliases||Rh polypeptide 1 (RhPI), Rh30A, RhIXB, Rhesus C/E antigens, CD_antigen: CD240CE|
|Organism||Homo sapiens (Human)|
RHCE may be part of an oligomeric complex that is likely to have a transport or channel function on the erythrocyte membrane. A recent study of the population of Sardinia showed that in the RHCE gene (rs630337), a non-coding variant was associated with erythrocyte sedimentation rate (ESR). This suggests a possible causal effect of this polymorphism on this inflammatory marker, although not found in the coding region of the gene.
Fig.1 The structure of Blood group Rh(CE) polypeptide.
In 1 (0.3%) and 17 (5%) cases, a rare Rh phenotype was predicted from RhCE molecular analysis, associated with a high prevalence antigen or a portion of RhCE antigen.
According to the results of this study, the authors suggest that all individuals with weak genotype D 4.2.2 should be screened for RHCE variants by the conventional molecular analysis system.
These results suggest that RH allelic variation in SCA patients is clinically relevant, and NGS technology can provide a comprehensive alternative to SNP-based testing.
These results suggest that knowledge of the distribution and prevalence of RH alleles in SCD patients and African-American donors is important for projects that implement RH genotype matching in SCD patients who have RH alleles and Clinically significant RH antibodies.
The authors conclude that antibodies to transformed patients depend on the trans RHCE allele
To obtain the soluble and functional target protein, the versatile Magic™ membrane protein production platform in Creative Biolabs enables many flexible options, from which you can always find a better match for your particular project. Besides, aided by our versatile Magic™ anti-membrane protein antibody discovery platform, we also provide customized anti-RHCE antibody development services.
Creative Biolabs' skillful scientists are glad to leverage our expertise and advanced technologies to help you with the member protein research. If you are interested, please feel free to contact us for more details.